Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
AbbVie’s CEO hails ‘exceptional’ psoriasis drug launch as Humira fadesThe bad news from AbbVie’s full year results was that inflammatory diseases blockbuster Humira “only” made around $19.2 Share XAbbVie’s CEO hails ‘exceptional’ psoriasis drug launch as Humira fadeshttps://pharmaphorum.com/news/abbvies-ceo-hails-exceptional-psoriasis-drug-launch-as-humira-fades/
AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie mergerAllergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy Share XAZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie mergerhttps://pharmaphorum.com/news/az-buys-back-rights-to-crohns-candidate-from-allergan-ahead-of-abbvie-merger/
Amgen strikes outcomes-based payment plan for Enbrel with AbarcaPharmacy benefit manager Abarca has announced a US reimbursement contract with Amgen for its Enbrel (etanercept) inflammatory diseases Share XAmgen strikes outcomes-based payment plan for Enbrel with Abarcahttps://pharmaphorum.com/news/amgen-strikes-outcomes-based-payment-plan-for-enbrel-with-abarca/
Roche backs Rituxan with further data in rare skin disease PVRoche’s Rituxan (rituximab) has been on the market for years as a blood cancer drug, and is finally Share XRoche backs Rituxan with further data in rare skin disease PVhttps://pharmaphorum.com/news/roche-backs-rituxan-with-further-data-in-rare-skin-disease-pv/
Roche’s Gazyva wins Breakthrough Therapy status for lupus nephritisRoche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, Share XRoche’s Gazyva wins Breakthrough Therapy status for lupus nephritishttps://pharmaphorum.com/news/roches-gazyva-wins-breakthrough-therapy-status-for-lupus-nephritis/
Novartis’ Cosentyx heads for fourth indicationNovartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it Share XNovartis’ Cosentyx heads for fourth indicationhttps://pharmaphorum.com/news/cosentyx-heads-for/
Could phase 3 trial win save AZ’s troubled Lupus drug?AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a Share XCould phase 3 trial win save AZ’s troubled Lupus drug?https://pharmaphorum.com/news/could-phase-3-trial-win-save-azs-troubled-lupus-drug/
Three years after approval, court blocks US launch of Enbrel biosimilarSandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel Share XThree years after approval, court blocks US launch of Enbrel biosimilarhttps://pharmaphorum.com/news/three-years-after-approval-court-blocks-us-launch-of-enbrel-biosimilar/
